Naloxone Accord (Naloxone Hydrochloride)

Naloxone, the active ingredient in Naloxone Accord, is an opioid antagonist presented as an injectable solution for intravenous use. It rapidly restores normal breathing and consciousness in patients experiencing life‑threatening respiratory depression, sedation and hypotension caused by opioid overdose in both adult and pediatric patients.

GNH USA supplies Naloxone Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance for emergency care providers. The product meets EU pharmacopoeial standards and is available for bulk procurement under controlled conditions.

Naloxone is an opioid antagonist used in emergency medicine to counteract the effects of opioid toxicity. - Opioid overdose: rapidly restores normal breathing and consciousness in patients experiencing life‑threatening respiratory depression. - Opioid‑induced respiratory depression: reverses hypoventilation caused by therapeutic or illicit opioid use. - Opioid toxicity: mitigates severe sedation, hypotension and miosis associated with high opioid plasma levels.

Naloxone may cause a range of adverse reactions, most of which are related to its rapid reversal of opioid effects.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Vomiting: occasional emesis after dosing. - Sweating: increased perspiration. - Tachycardia: elevated heart rate.

Serious or Rare Side Effects: - Seizures: convulsive episodes, particularly in susceptible individuals. - Cardiac arrhythmias: irregular heart rhythms. - Acute opioid withdrawal: severe symptoms such as vomiting, diarrhea, muscle aches.

When using Naloxone Accord, several safety considerations should be observed to ensure effective and safe reversal of opioid toxicity. - Assess airway: verify patency and be prepared for airway support. - Monitor vital signs: continuously observe respiratory rate, oxygen saturation and blood pressure after administration. - Anticipate withdrawal: be aware that abrupt reversal can precipitate acute opioid withdrawal symptoms. - Avoid hypersensitivity: do not administer to patients with known allergy to naloxone or formulation components. - Adjust for hepatic impairment: consider reduced clearance in severe liver disease and monitor response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Naloxone can interact with other medications, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Opioid agonists: concurrent use may precipitate severe withdrawal and reduce analgesia. - Mixed agonist‑antagonist opioids (e.g., buprenorphine): may cause unpredictable effects and loss of analgesia.

Moderate Interactions (Monitor Closely): - Central nervous system stimulants: may enhance tachycardia and hypertension. - Drugs lowering seizure threshold (e.g., bupropion): increase risk of seizures when naloxone is administered. - MAO inhibitors: may potentiate hypertensive responses.